



ASX Release

Date of 2017 Annual General Meeting

20 September 2017, Sydney, Australia: Viralytics Limited (ASX: VLA, OTC: VRACY) advises that its 2017 Annual General Meeting will be held on Wednesday, 22 November 2017.

About VIRALYTICS and CAVATAK™

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK™, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers. Intratumoural, intravenous and intravesicular delivery routes are under investigation. Two combination studies with checkpoint inhibitors are underway in advanced melanoma patients, as well as a combination study of CAVATAK and KEYTRUDA in late-stage lung and bladder cancer patients.

Further details on our clinical and pre-clinical data can be found at:
<http://www.viralytics.com/our-pipeline/clinical-trials/>

CAVATAK is a proprietary bioselected formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Viralytics Investor/Media Contact:

Dr Malcolm McColl
Managing Director
+61 2 9988 4000

Mr Robert Vickery
Chief Financial Officer
+61 2 9988 4000